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Cytochrome c oxidase defectsMitochondrialmetabolic dysfunction is often seen in cancers. This paper shows that the defect in amitochondrial
electron transport component, the cytochrome c oxidase (CcO), leads to increased glycolysis and carcinogenesis.
Usingwhole genomemicroarray expression analysiswe show that genetic silencing of the CcO subunit Cox4i1 in
mouse C2C12 myoblasts resulted in metabolic shift to glycolysis, activated a retrograde stress signaling, and in-
duced carcinogenesis. In the knockdown cells, the expression of Cox4i1 was less than 5% of the control and the
expression of the irreversible glycolytic enzymes (Hk1, Pfkm and Pkm) increased two folds, facilitatingmetabolic
shift to glycolysis. The expression of Ca2+ sensitive Calcineurin (Ppp3ca) and the expression of PI3-kinase (Pik3r4
and Pik3cb) increased by two folds. This Ca2+/Calcineurin/PI3K retrograde stress signaling induced the up-
regulation of many nuclear genes involved in tumor progression. Overall, we found 1047 genes with 2-folds ex-
pression change (with p-value less than 0.01) between the knockdown and the control, among which were 35
up-regulated genes in pathways in cancer (enrichment p-value less than 10−5). Functional analysis revealed
that the up-regulated genes in pathways in cancer were dominated by genes in signal transduction, regulation
of transcription and PI3K signaling pathway. These results suggest that a defect in CcO complex initiates a retro-
grade signaling which can induce tumor progression. Physiological studies of these cells and esophageal tumors
from human patients support these results. GEO accession number = GSE68525.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).yoblasts
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3. Experimental Design, Materials and Methods
3.1. Sample preparation
Cells were grown in Dulbecco's Modiﬁed Eagle medium supple-
mented with 10% fetal bovine serum and 0.1% penicillin/streptomycin.
In case of Cox4i1 silenced (C4KD) cells, themediumwas further supple-
mented with 1 mM Pyruvate and 50 μg/ml Uridine. RNA was prepared
using Qiagen Rneasy kit following manufacturer's instructions. 5.5 μg
single-stranded cDNAwas fragmented and labeled using the Affymetrix
GeneChip WT Terminal Labeling kit (PN: 900671). Labeled cDNA
(3.25 μg) was hybridized for 17 h at 45°C to Affymetrix GeneChip
Mouse Gene 2.0ST Arrays (PN: 902118).
3.2. Microarray analysis
The data were processed by Affymetrix Expression Console using
Probeset-Summarize-Engine with default setting of the robust multi-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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each probeset of the array (in log2 unit, online ﬁle: rma-gene-
full.summary.txt). For quality control, we performed principal
component analysis (PCA) based on RMA expression levels of the sam-
ples. The projection to the most dominant two components is shown in
Fig. 1a. The control samples formed a single cluster separable from the
knockdown. However, the knockdown samples are further branched
into two groups. The grouping is also clearly shown (Fig. 1b) by the cor-
relation coefﬁcient value (with each probe mean over all samples re-
moved) between two samples: if the two samples come from the
same group, the value is high (above 0.6); if they come from different
groups, the value is low or negative. Further investigation of the biolog-
ical samples showed that C4KD1 and C4KD2 cells contained nearly 90%
reduced Cox4i1 mRNA and protein as compared to control cells [2],
while in C4KD3 cells the reduction was not as much (probably due to
a less effective population selection by antibiotic resulting a mixture
of knockdown and non-knockdown cells). This is consistent with
microarray results: for both C4KD1 and C4KD2 the reduction were
~20 folds, for C4KD3 only ~2 folds. In the following analysis, C4KD3
was excluded.Fig. 1. Quality control for data analysis. The array expression data (from all 41,345 probes) of e
separation of 6 samples into three groups. This separation is also shown in the 6×6matrix of th
for signiﬁcant fold change in individual gene expression: the absolute fold change has to be bigg
analysis, the selected genes are ranked by p-value and are further selected by Benjamini-Hoch3.3. Statistical analysis
Fold changes are presented as the mean ± s.e.m. (standard error of
the mean) and p-values were determined by one-tailed Welch's t-test,
which is used to test the hypothesis that two populations have equal
means and is more reliable than Student's t-test when the samples
from two populations have unequal variances and unequal sample
sizes [3]. So for a statistic t and a degrees of freedom v, the p-value is cal-
culated by
1
2
I v
vþt2
v
2
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1
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 
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where I is the regularized incomplete beta function. The statistic t is de-
ﬁned by the following formula:
t ¼ m1−m2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s1 þ s2
p ð2Þach sample are projected to the ﬁrst two components of PCA, P1 and P2 in a, showing the
e correlation coefﬁcients between samples (b). The plot in (c) shows the selection criteria
er than 20.5 (red and blue dots), and the p-value has to be smaller than 0.05. For functional
eberg method to limit FDR (d).
Table 1
Top 64 most enriched pathways in the C4KD cells compared to the control cells.
The top pathways were selected with the number of hits ≥ 20 and the p-value b 0.15.
Hits Size % p-value Kegg id Name of pathway
330 1271 26 1.3e-11 01100 Metabolic pathways
127 397 32 6.4e-11 05200 Pathways in cancer
95 352 27 5.3-e05 04151 PI3K-Akt signaling pathway
74 232 32 6.3e-07 05203 Viral carcinogenesis
73 206 35 6.1e-09 05205 Proteoglycans in cancer
71 276 26 1.8e-03 05206 MicroRNAs in cancer
68 254 27 7.2e-04 04010 MAPK signaling pathway
66 208 32 3.0e-06 04510 Focal adhesion
64 170 38 3.4e-09 03013 RNA transport
64 218 29 6.3e-05 01130 Biosynthesis of antibiotics
64 235 27 6.3e-04 04144 Endocytosis
60 145 41 1.1e-10 03010 Ribosome
58 230 25 6.9e-03 04014 Ras signaling pathway
54 214 25 8.7e-03 04015 Rap1 signaling pathway
50 133 38 1.8e-07 03040 Spliceosome
49 118 42 5.5e-09 04919 Thyroid hormone signaling pathway
48 177 27 3.0e-03 05202 Transcriptional misregulation in cancer
45 168 27 5.1e-03 04141 Protein processing in endoplasmic reticulum
45 172 26 8.1e-03 04022 cGMP-PKG signaling pathway
45 179 25 1.7e-02 00230 Purine metabolism
44 198 22 1.1e-01 04062 Chemokine signaling pathway
43 139 31 2.7e-04 00190 Oxidative phosphorylation
43 143 30 5.4e-04 04120 Ubiquitin mediated proteolysis
41 142 29 1.7e-03 04910 Insulin signaling pathway
41 129 32 2.0e-04 04152 AMPK signaling pathway
41 174 24 5.5e-02 04145 Phagosome
40 181 22 1.3e-01 04020 Calcium signaling pathway
40 143 28 3.6e-03 04310 Wnt signaling pathway
39 159 25 3.5e-02 04921 Oxytocin signaling pathway
39 125 31 4.3e-04 04110 Cell cycle
38 154 25 3.4e-02 04390 Hippo signaling pathway
37 104 36 2.8e-05 00240 Pyrimidine metabolism
37 124 30 1.5e-03 04142 Lysosome
37 103 36 2.2e-05 04922 Glucagon signaling pathway
36 134 27 1.1e-02 04068 FoxO signaling pathway
35 122 29 4.0e-03 04722 Neurotrophin signaling pathway
35 115 30 1.3e-03 04114 Oocyte meiosis
34 140 24 5.2e-02 04530 Tight junction
33 140 24 7.8e-02 04550 Signaling pathways regulating pluripotency
of stem cells
31 94 33 5.6e-04 00564 Glycerophospholipid metabolism
30 109 28 1.3e-02 04066 HIF-1 signaling pathway
29 101 29 8.1e-03 05231 Choline metabolism in cancer29
29 117 25 5.5e-02 01200 Carbon metabolism
28 124 23 1.5e-01 04071 Sphingolipid signaling pathway
27 87 31 3.3e-03 04540 Gap junction
26 88 30 7.9e-03 04512 ECM-receptor interaction
26 96 27 2.5e-02 03015 mRNA surveillance pathway
25 83 30 7.0e-03 03008 Ribosome biogenesis in eukaryotes
25 99 25 5.9e-02 04915 Estrogen signaling pathway
25 67 37 2.3e-04 04115 p53 signaling pathway
25 89 28 1.8e-02 04912 GnRH signaling pathway
25 82 30 5.9e-03 04210 Apoptosis
25 72 35 8.0e-04 04920 Adipocytokine signaling pathway
23 74 31 6.3e-03 04520 Adherens junction
23 87 26 4.3e-02 04012 ErbB signaling pathway
23 83 28 2.6e-02 03018 RNA degradation
23 82 28 2.2e-02 003320 PPAR signaling pathway
22 74 30 1.3e-02 04917 Prolactin signaling pathway
22 82 27 4.0e-02 04070 Phosphatidylinositol signaling system
22 66 33 2.9e-03 05230 Central carbon metabolism in cancer
21 82 26 6.9e-02 04350 TGF-beta signaling pathwa
20 79 25 8.2e-02 01230 Biosynthesis of amino acids
20 66 30 1.4e-02 00010 Glycolysis / Gluconeogenesis
20 61 33 5.4e-03 04150 mTOR signaling pathway
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where v1 and v2 are the 1st and 2nd sample size, respectively. All calcu-
lations are performed using RMA expression levels, i.e., in log2 unit. For a
given gene, a fold change N20.5 with a p-value b0.05was considered sta-
tistically signiﬁcant. Fig. 1b shows the distribution of fold change versus
p-value for the full probeset of the Affymetrix GeneChip Mouse Gene
2.0ST Arrays. Out of 41,345 probes, 6049 had statistically signiﬁcant
fold change (red dots in Fig. 1c). Among those are 4908 uniquely iden-
tiﬁed genes (out of 26,515 Entrez genes of the array). Each individual
gene expression presented in the paper is among those.
3.4. Pathway analysis
The list of genes with signiﬁcant fold change was uploaded to KEGG
Mapper to search pathways (http://www.genome.jp/kegg/tool/map_
pathway1.html, [4]). To further narrow down the list of pathways, we
calculated the p-value of pathway enrichment. With H the hits, i.e., the
number of genes from our list present in a pathway of size S,N the num-
ber of genes of the list, and T the total number of genes of the array, the
enrichement p-value was determined by
1−F H−1; T; S;Nð Þ ð4Þ
in which F(h; t, s, n) is the hypergeometric cumulative distribution
function
F h; t; s;nð Þ ¼
Xi¼h
i¼0
s
i
 
t−s
n−i
 
t
n
  ð5Þ
We foundN=4908, used T=26515 and retrieved S from theKEGG da-
tabase (July, 2015). Table 1 shows the top 64 most enriched
pathways—excluding the ones in organ functions and speciﬁc diseases.
3.5. Functional analysis
A more stringent criteria was used to select genes for functional an-
notation: a fold change N2 with a p-value b0.01. There were 1861
probes satisﬁed this criteria. To control the false discovery rate (FDR),
the Benjamini-Hocheberg procedure [5] was applied to select further:
for the FDR at level q, ﬁnd the largest k such that
pk≤
k
m
q ð6Þ
then select i = 1...k, where pk is the p-value of m genes with lowest p-
values. For a FDR of 0.01, 1860 out 1861 probes were selected (Fig. 1d).
Among those were 656 up-regulated and 391 down-regulated uniquely
identiﬁed genes (seeﬁlesmypup.txt.2x0.01p andmypdown.txt.2x0.01p).
The generated gene list was functionally annotated using DAVID 6.7
(http://david.abcc.ncifcrf.gov/, [6]) with default setting (online ﬁle:
myfa_table_all.txt.2x0.01p). The functional groups of genes were extract-
ed from the annotated ﬁle using the corresponding terms (e.g. “signal
transduction,”) with our own script (online ﬁle: myfa.csh).
4. Results
4.1. Enriched expression in metabolic, cancer and PI3K signaling pathways
Metabolic Pathways, Pathways in Cancer and PI3K-Akt Signaling
Pathway were the top three pathways enriched with the genes ofsigniﬁcant expression change due to the CcO complex defect
(Table 1). Among the three, Pathways in Cancer and PI3K-Akt Signaling
Pathway had a lots of overlaps while they had little overlaps with
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ways were distributed in different pathways of metabolism (Fig. 2b).
Oxidative Phosphorylation was the leading one. Another enriched one
was Glycolysis/Gluconeogenesis. Glycolysis is known to be responsible
for energy generation if Oxidative Phosphorylation is interrupted. The
127 genes enriching Pathways in Cancer were sub-divided into many
pathways (Fig. 2c). Interestingly, genes in PI3K-Akt Signaling Pathway
accounted for one third overall and contributed about half to others ex-
cept Wnt and Hippo signaling pathways.
The 95 genes enriching PI3K-Akt Signaling Pathway overlapped
most signiﬁcantly with pathways in cancer and also overlapped with
additional signaling pathways (Fig. 2d). Especially interesting were
AMPK and mTOR pathways, known to be activated during metabolic
stress. Most of these pathways were among the top 64 enriched path-
ways and accounted for most of the signaling pathways of the top 64.
One signiﬁcant exception was Calcium Signaling Pathway (Table 1). It
is signiﬁcant because this pathway is involved in a unique retrograde
signaling cascade responding to [Ca2+]c elevation during disruptions
of the mitochondrial electron transport chain [7]. We show in the fol-
lowing sections with speciﬁc expression changes that the defect in
CcO complex caused metabolic shift to glycolysis, induced calcium de-
pendent retrograde signaling, activated PI3K pathway and resulted in
carcinogenesis.
4.2. Disruption of CcO complex leading to metabolic shift to glycolysis
The expression of Cox4i1 in the cells with Cox4i1 silenced by shRNA,
referred as CcO4KD cells throughout this paper, was less than 5% of theFig. 2. Threemajor pathways of signiﬁcantly regulated genes of CcO4KD cells—Metabolic Pathw
Metabolic Pathways' overlaps with others; c, Pathways in Cancer's overlaps with others; d, PI3control with scrambled shRNA (Fig. 3a). The mRNA expression levels of
the irreversible glycolytic enzymes, Hexokinase (Hk1, Fig. 3b),
Phosphofructokinae (Pfkm, Fig. 3c) and Pyruvate kinase (Pkm, Fig. 3d)
had approximately two-folds increase. Fig. 3 also shows the mRNA ex-
pression levels of four other enzymes in the glycolytic pathway with
the most fold-changes (Acss2, Adh1, Adh7 and Aldh2 in Fig. 3e to h).
They were all up-regulated in CcO4KD cells and are downstream of
glycolysis—important for processing pyruvate produced during glycoly-
sis. In agreement with these data, CcO activity was reduced by about
90%, theHk and Pfk activities increased about two folds, and glucose up-
takewasmore than two-fold higher in CcO4KD cells [2]. These indicated
that silencing Cox4i1 lead to the disruption of CcO activity and caused
metabolic shift to glycolysis.
4.3. Activation of Calcium dependent retrograde signaling pathway
The mitochondrial stress and the loss of mitochondrial mem-
brane potential were indicated by the enrichment of Calcium Sig-
naling Pathway (Table 1) and in particular by a two-fold increase
in the expression level of Ca2+ sensitive Calcineurin (Ppp3ca, Fig.
4a). This signal in response to sustained elevation of [Ca2+]c had
been shown to activate a set of stress responsive transcription fac-
tors: NFkB, NFAT and CREB [7]. This was consistent with the in-
creased expression levels of Nfkb1, Nfkb2, Rela, Nfatc1, Nfatc3,
Creb3l1 and Creb3l2 (Fig. 4b to h). In addition to those, this retro-
grade stress signaling induced increased expression of many
genes involved in tumor progression. In particular, Tgfb1 and
Mmp16 had 2 to 3 folds expression increase (Fig. 5a and b). Inays, Pathways in Cancer and PI3K-Akt Signaling Pathway: a, overlaps between the three; b,
K-Akt Signaling Pathway's overlaps with others.
Fig. 3. Knock-down of the expression level of cytochrome c oxidase (Cox4i1 in a), and expression up-regulation of all three irreversible glycolytic enzymes Hexokinase (Hk1 in b), Phos-
phofructokinase (Pfkm in c) and Pyruvate Kinase (Pkm in d), as well as four other enzymes downstream of glycolysis: Acss2, Adh1, Adh7 and Aldh2 (e, f, g and h).
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CcO4KD cells; while for the cells further treated with BAPTA, a Ca2+
chelator, or FK506, a speciﬁc Calcineurin inhibitor, the up-regulation
of Tgfb1 and Mmp16 was signiﬁcantly attenuated and the glucoseFig. 4. Up-regulation of Calcineurin (Ppp3ca in a) and Calcineurin pathway: NFkB (Nfkb1 in b,
Creb3l2 in h).uptake was signiﬁcantly inhibited comparing to untreated cells [2].
These indicated that the Calcineurin mediated retrograde signaling
pathway played an important role in metabolic shift to glycolysis and
carcinogenesis.Nfkb2 in c and Rela in d), NFAT (Nfatc1 in e and Nfatc3 in f), and CREB (Creb3l1 in g and
Fig. 5.Up-regulationof seven genes related to cancer: Tgfb1 in a,Mmp16 inb, Ar in c, Col4a5 ind, Tgfb2 in e, Arnt2 in f andBmp4 in g. Down-regulation of one gene related to cancer: Ccne1 inh.
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The activation of PI3-kinase pathwaywas indicated by a two-fold in-
crease in expression level of PI3-kinase—of both catalytic and regulatory
subunits Pik3cb and Pik3r4 (Fig. 6a and b). It has been shown that thisFig. 6. Up-regulation of PI3-kinase (Pik3cb in a and Pik3r4 in b) and PI3-kinase papathway is a major determinant of the glycolytic phenotype through
Akt1 and Mtor signaling and subsequent downstream Hif1a transcrip-
tion factor activation [8]. In addition to increased expression of Mtor
and Hif1a (Fig. 6c and d) in CcO4KD cells, there were also increased ex-
pression levels for genes further down stream [9] of this pathwaythway: Mtor in c, Hif1a in d, Ddit4 in e, Tsc2 in f, Foxo1 in g, and Prkca in h.
Table 2
38 signiﬁcantly regulated genes in pathways in cancer. 35 were up-regulated in CcO4KD
and only 3were down-regulated (Ccne1, Ccne2 and Tceb1). The genes were selectedwith
a fold change ≥2 and a p-value b0.01. The fold change is expressed in log2 unit.
Symbol Fold p-Value Entrez Gene name
Ar 1.65 2e-04 11,835 Androgen receptor
Arnt2 2.45 1e-03 11,864 Aryl hydrocarbon receptor nuclear
translocator 2
Bmp4 3.25 3e-04 12,159 Bone morphogenetic protein 4
Ccne1 −1.12 1e-03 12,447 Cyclin E1
Ccne2 −1.09 3e-04 12,448 Cyclin E2
Cebpa 1.54 2e-03 12,606 CCAAT/enhancer binding protein (C/EBP), α
Col4a2 1.45 2e-04 12,827 Collagen, type IV, α 2
Col4a5 1.69 1e-03 12,830 Collagen, type IV, α 5
Col4a6 1.02 1e-04 94,216 Collagen, type IV, α 6
Dapk2 1.45 1e-03 13,143 Death-associated protein kinase 2
Ep300 1.03 2e-05 328,572 E1A binding protein p300
Figf 1.31 1e-03 14,205 c-fos induced growth factor
Foxo1 1.32 1e-03 56,458 Forkhead box O1
Fzd4 1.08 4e-03 14,366 Frizzled homolog 4 (Drosophila)
Fzd6 1.56 4e-03 14,368 Frizzled homolog 6 (Drosophila)
Gli2 1.07 5e-03 14,633 GLI-Kruppel family member GLI2
Jak1 1.02 2e-05 16,451 Janus kinase 1
Kitl 1.46 2e-03 17,311 Kit ligand
Lama2 1.49 1e-04 16,773 Laminin, α 2
Lamb3 1.35 6e-04 16,780 Laminin, β 3
Lamc1 1.18 3e-05 226,519 Laminin, γ 1
Met 1.13 2e-03 17,295 Met proto-oncogene
Ncoa4 1.05 2e-04 27,057 Nuclear receptor coactivator 4
Nfkb2 1.03 9e-04 18,034 Nuclear factor of κ light polypeptide gene
enhancer in B cells 2
Pdgfb 1.74 8e-04 18,591 Platelet derived growth factor, B
polypeptide
Ppard 1.15 9e-04 19,015 Peroxisome proliferator activator receptor
delta
Rxra 1.03 2e-04 20,181 Retinoid X receptor α
Stat1 1.23 1e-03 20,846 Signal transducer and activator of
transcription 1
Stat5a 1.02 1e-04 20,850 Signal transducer and activator of
transcription 5A
Tceb1 −1.09 1e-03 67,923 Transcription elongation factor B (SIII),
polypeptide 1
Tcf7 1.16 6e-03 21,414 Transcription factor 7, T cell speciﬁc
Tcf7l2 1.05 4e-05 21,416 Transcription factor 7 like 2, T cell speciﬁc,
HMG box
Tgfb1 1.00 6e-04 21,803 Transforming growth factor, β 1
Tgfb2 2.27 1e-05 21,808 Transforming growth factor, β 2
Tgfbr2 1.36 4e-05 21,813 Transforming growth factor, β receptor II
Wnt10a 1.58 9e-04 22,409 Wingless related MMTV integration site 10a
Wnt4 1.16 7e-03 22,417 Wingless-related MMTV integration site 4
Wnt7b 1.40 3e-04 22,422 Wingless-related MMTV integration site 7B
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well as other genes related to pathways in cancer (Fig. 5). Aerobic gly-
colysis supports various biosynthetic pathways and, consequently, the
metabolic requirements for proliferation. Consistent with this, the
CcO4KD cells developed anchorage independent growth, an important
hallmark of malignant cells, and further treatment with Wortmannin,
a PI3-kinase inhibitor, attenuated the glucose uptake and inhibited the
colony formation of those cells [2]. These indicated that the PI3-kinase
pathway played a crucial role in metabolic shift to glycolysis and in
tumor progression.
4.5. Oncogenes enriched transcription proﬁles
Bmp4, Arnt2, Tgfb2, Col4a5 and Ar (shown in Fig. 5c to g) were the
ﬁve most up-regulated genes in Pathways in Cancer. Ccne1 (shown inFig. 7. Functional groups of signiﬁcantly regulated genes of CcO4KD cells: a, the number of
geneswith signiﬁcant fold-changes in different functional groups; b, the Venndiagrams of
up-regulated genes in signal transduction (pink), regulation of transcription (green) and
pathways in cancer (brown); c, the Venn diagrams of up-regulated genes in signal trans-
duction (pink), PI3K pathway (green) and pathways in cancer (brown).
Fig. 8.The comparison between the expression fold changes of four genes frommicroarray
and thosemeasured by RT-PCR in a log-log plot. The straight line lieswhere they are equal.
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Col4a5 and Ccne1 are in PI3K-Akt Pathway and their corresponding
up and down regulation are consistent with their role in cancers. Fur-
thermore, Ar, Bmp4 and Tgfb2 are involved in signal transduction and
Ar, Arnt2 and Bmp4 are involved in regulation of transcription. To gain
additional understanding of functional roles of the most signiﬁcantly
regulated genes of CcO4KD cells, we further narrowed down the list of
genes and did functional annotation of the list. There were 1047 genes
with 2-fold or more expression change and p-value less than 0.01. The
distribution of those genes in the three dominate pathways and 10 dif-
ferent functional groups is shown in Fig. 7a. Among those were 38Fig. 9. Up-regulation of PGC-1α (Ppargc1a in a) and its interaction partners: Crebbp in b, Ppa
regulator LKB1 (Stk11 in g) and a downstream gene Srebf1 in h.signiﬁcantly regulated genes in Pathways in Cancer (enrichment p-
value less than 10−6). Table 2 shows the fold changes and the p-
values of the 38 genes. 35 genes in Pathways in Cancer were up-
regulated (enrichment p-value less than 10−5). 24, 15 and 11 of these
up-regulated genes in pathways in cancer are in functional groups of
signal transduction, regulation of transcription and PI3K pathway, re-
spectively. There were extensive overlaps (11) between those in signal
transduction and regulation of transcription (Fig. 7b). There were also
overlaps (5) between those in signal transduction and PI3K pathway
(Fig. 7c). Therewas only one (Rxra) overlap between those in regulation
of transcription and PI3K pathway. Only two genes (Dapk2 and Ncoa4)
in pathways in cancer were not in any of the other three functional
groups. Interestingly, none of genes in pathways in cancer was in meta-
bolic pathway. It appears that CcO defects induced Calcineurin/PI3K
retrograde signaling which in turns induced up-regulation of genes in-
volved in signal transduction and regulation of transcription, up-
regulation of genes related to pathways in cancer, and carcinogenesis.
5. Discussion
The whole genome microarray analysis of the knockdown and con-
trol cells gave the insight into the magnitude of systematic changes of
gene expressions and also enabled the global analysis of pathways and
functional groups of many genes efﬁciently. It is interesting to know
the accuracy of individual fold change of gene expression estimated
from the experimental array. For some of the genes, the relative
mRNA levels were also measured by RT-PCR [2]. Fig. 8 shows the com-
parison between the results of microarray and RT-PCR. The agreement
is quite good. The that fold change estimated by the array is slightly
on the conservative side. This gave conﬁdence to use the array not
only for the global analysis but also for measuring relative change of in-
dividual gene's mRNA level.
The pathway analysis also indicated that PPAR (PGC-1α) signaling
pathway was activated. PGC-1α is another regulator of mitochondrial
biogenesis and function. It has been shown that PGC-1α has a positiverg in c, and Rxra in d. Up-regulation of AMPK (Prkaa1 in e and Prkaa2 in f), its upstream
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can interactwith, and regulate the activities of, cAMP response element-
binding protein (CREB). Fig. 9a to d shows the up-regulation of PGC-1α
(Ppargc1a) and its interaction partners Crebbp, Pparg, and Rxra. Anoth-
er important pathway activated was the AMP-activated protein kinase
(AMPK) signaling pathway. AMPKplays an important role in insulin sig-
naling, glucose uptake, and energy homeostasis and is involved in PGC-
1α-mediated mitochondrial biogenesis. The microarray analysis indi-
cated up-regulation of AMPK (Prkaa1 and Prkaa2 in Fig. 9e and f) and
its up-stream regulator LKB1 (Stk11, Fig. 9g) aswell as two downstream
genes (Srebf1, Fig. 9h; and Tsc2, Fig. 6f). This is puzzling since AMPK is
supposed to down-regulated Srebf1 and Tsc2 and to be a metabolic
checkpoint to control cell proliferation when activated under energy
stress. But it was not doing any of those in CcO4KD cells. The role of
AMPK pathway in Cox4i1 knockdown needs to be studied further.
Our physiological experiments have shown that CcO dysfunction is a
possible biomarker for cancer progression in digestive diseases such as
esophageal tumors [2]. It will be very interesting to conduct a whole ge-
nome expression analysis on such tumors and to compare the results
with those presented in this paper. Such comparisonwill help to further
understand the pathways of this type of tumor progression and to ﬁnd
possible pathway-based methods of diagnosis and treatment.
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